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children with grade I and II dengue was higher in this epi-
demic than in the previous epidemic. Epistaxis was the
most common bleeding manifestation this time in contrast
to haematemesis in previous epidemics.5,6 Bleeding manifes-
tations did not vary significantly, with platelet count (P .
0.05). This may be explained by the fact that there are mul-
tiple factors involved in the pathogenesis of haemorrhagic
manifestation during DHF, and thrombocytopaenia is just
one of them.8 None of the patients developed manifestations
of DSS. Neurological manifestations such as convulsions and
encephalopathy were not noted in any patient. There was no
mortality, which may be due to the fact that severe forms of
DHF, such as DHF IV and DSS, were not included in the
study. Further, mortality has been gradually decreasing over
the years due to increased awareness, faster transport and
better management protocols.
LFTs revealed an abnormal SGPT (.40 IU/L) in 22
(64.7%) cases, compared to 84% in the study by Mohan
et al.9 and 63.6% in the 2001 Chennai epidemic.10
Enzymes are usually raised after the third day. Alkaline phos-
phatase was raised in 35.4% cases and serum bilirubin of
more than 1 mg% was seen in 8.8%.
There was no overt hyperbilirubinaemia in the majority of
cases, but an alteration in enzymes was seen in a number of
patients. This may have implications in the pathogenesis of
haemorrhagic manifestations, as coagulation profiles may
also be affected, and there may be variations in clinical
profile. Hence liver enzymes must be monitored in all
cases. Alterations in liver functions were not significantly
influenced by platelet count, age and sex in the present study.
Initial haematocrit was low in a large number of cases due
to the high prevalence of anaemia in the community.1,11
However, evidence of plasma leakage (such as pleural effu-
sion or ascites) or rising haematocrit was present in all
cases. Similar findings were seen in a previous study from
Delhi.5
We observed that the clinical features of DHF varied from
the previous epidemic. Hepatic dysfunction with increased
levels of serum enzymes was common in DHF. Bleeding
manifestations and an alteration in biochemical profile are
not significantly influenced by platelet count, age and sex
of the patients.
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Summary This study shows that cabergoline (single oral-
dose) is an acceptable, safe and effective drug for sup-
pressing puerperal lactation. It could be of operational
benefit not only forartificial feeding, but also for weaning
in those that breast-feed within preventive
mother-to-child HIV transmission programmes in
resource-limited settings.
Introduction
During the initiation of a prevention of mother-to-child trans-
mission of HIV (PMTCT) in Thyolo district of rural Malawi
(where both exclusive breast and artificial feeding are avail-
able as infant feeding options) group discussions were held
with mothers and village elders, and a key issue of concern
was ‘how breast milk suppression would be achieved in
those who chose the artificial feeding option?’. We were
made to understand that engorged and dripping breasts
were social taboos as it is believed to induce future illnesses
in the mother and child. Mothers seen with such breasts
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thus run the risk of being compelled by household members
to allow the newborn to suck on the breasts. This practice
constitutes a potential risk due to mixed feeding among
those who choose artificial feeding but have delays in
breast milk suppression in the early post-natal period.
Although current Malawi and World Health Organization
guidelines recommend minimal breast compression for sup-
pressing physiological lactation, we felt this strategy would
be inappropriate in our setting and that mothers needed a
more effective and rapid alternative.1,2
In the industrialized world, the drug cabergoline, adminis-
tered in a single oral-dose is used for inhibiting physiological
lactation.3,4 The drug is a prolactin inhibitor and acts by stop-
ping the brain from making and releasing the hormone ‘pro-
lactin’ from the pituitary gland. When used immediately after
delivery it prevents the ‘onset’ of normal lactation. There are,
however, no published reports on the use of this drug among
mothers in Africa.
We report on the acceptability, effectiveness and safety of
cabergoline for routine lactational suppression in rural
Malawi.
Methods
This study was conducted in Thyolo, a rural area of southern
Malawi with approximately 550,000 inhabitants. The study
was conducted over an eight-week period in early 2004 and
included consecutive HIV-positive mothers who opted for
the breast feeding option. The main public hospital (Thyolo
Hospital) was the site of the study and the procedures and
steps for PMTCT in this hospital have been described
previously.5
For mothers choosing the artificial feeding option, caber-
goline was offered in a single oral-dose of 1 mg to be
taken in the delivery room. Contraindications included a
history of hypersensitivity to ergot alkaloids or bromocrip-
tine, toxaemia of pregnancy and essential hypertension.
Side-effects were monitored clinically and mothers were
interviewed and examined on day 1, 2 and 3 post-partum.
Specific symptoms sought for included nausea, vomiting,
epigastric pain, breast pain, dizziness, palpitations and
visual defects. The pulse rate, blood pressure and vision
were examined.
The PMTCT register and an additional pre-tested question-
naire were used to gather information related to the study.
Data was analysed using epiinfo 6.4 (Centers for Disease
Control, Atlanta, USA). Ethical approval was received from
the ethical review boards of both the Ministry of Health of
Malawi and Medecins Sans Frontieres.
Results
A total of 104 HIV-positive mothers received cabergoline of
whom six declined to participate in the study as they pre-
ferred to leave the hospital the day after delivery. Of the 98
mothers (median age 26 years) for whom data is available,
the great majority (90%) came from villages. Median
parity was 4 (range 1–8), 90% were married and the
average educational level was 3.9 years in school.
Table 1 summarizes the findings related to acceptability
and effectiveness. Four (4%) mothers experienced minor
side-effects: of these, two (2%) complained of dizziness
after administration and two (2%) experienced epigastric
pain, both of which cleared before discharge on the third
day after delivery.
Discussion
This study shows that a single oral-dose of cabergoline is
safe, effective and highly acceptable for suppressing puerp-
eral lactation. This is one of the first reports on the use of
cabergoline in sub-Saharan Africa. When compared to
minimal breast compression there are a number of potential
operational advantages of using this drug.
First, transmission of the HIV virus through breast feeding
accounts for one-third to one-half of all mother-to-child HIV
transmission (MTCT) – this risk remains unaffected by
peri-partum antiretroviral drug prophylaxis.6 In settings
where exclusive artificial feeding is feasible and safe, admin-
istration of this drug in the maternity is safe and easy (single
oral-dose) and results in rapid suppression of lactation. This
intervention, unlike breast compression1 which can take as
long as three to seven days, is not associated with painful
breast engorgements or added health risks on breast health
and, because it is so convenient, is clearly more ‘mother
friendly’.
Second, the cumulative probability of the child acquiring
HIV is related to episodes of mixed feeding and breast
health problems, particularly mastitis.6,7 As suppression of
puerperal lactation with cabergoline is relatively abrupt, the
Table 1 Acceptability of cabergoline among mothers
opting for artificial feeding in a preventive mother-to-child
HIV transmission (PMTCT) programme in Thyolo, Malawi
Variable Number (%)
Mothers interviewed 98
Heard about cabergoline prior to interview 98 (100)
Source of information (cabergoline)
Antenatal services at hospital 69 (70)
Maternity room 8 (8)
Mothers in the community 1 (1)
Health centre 1 (1)
Combined (more than one of the above) 9 (20)
Maximum time required for breast milk
suppression (days)
1 (range 0–1)
Mothers considering cabergoline effective 98 (100)
Had past experience with ‘other methods’ of breast
milk suppression
31 (32)
Traditional medicine 26 (23)
Breast compression 1 (1)
Both 4 (4)
Preferred choice among ‘other methods’ if
cabergoline was not available (n-31)
Traditional medicine 23 (74)
Breast compression 2 (6.5)
Both 1 (3)
Don’t know 5 (16)




What would be your infant feeding choice if
cabergoline was not available?
Artificial feeding 89 (91)
Breast feeding 9 (9)
Why would you choose artificial feeding if
cabergoline was not available? (n-89)
Because I want to reduce the chance of infecting
my baby with HIV
82 (93)
Because I reduce the chance if infecting my baby
and I get free milk.
7 (7)
Why would you choose breast feeding if
cabergoline was not available? (n-9)
Because I might end up with mixed feeding due
to social pressure (as a result of engorged
breasts)
6 (67)
Because I do not know of any other method to
suppress breast milk
3 (33)
Mothers who would like cabergoline to be
available in PMTCT routinely
98 (100)
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potential risk for mixed feeding – particularly mastitis
(associated with engorged breasts) – is avoided.
Third, in settings such as ours, where social taboos linked
to engorged and dripping breasts may be of concern, the use
of a rapid and effective option for breast milk suppression is
likely to minimize the social pressure on mothers and facili-
tate empowerment.
Finally, the drug is likely to be useful for ‘weaning’ among
those who opt for exclusive breast feeding, as transition from
breast milk to other feeds can often be relatively abrupt. A
dried-up breast will avoid the possibility of feeding with
breast milk and other feeds for greater than one day, and
this might favourably impact upon HIV-transmission.
About one in three mothers in our setting were aware of
other methods of breast milk suppression, namely traditional
medicine or breast compression. Although breast com-
pression is recommended for suppression of lactation in
resource-limited settings,1,2 this method had low acceptabil-
ity, and, in the absence of cabergoline, the great majority
of mothers would have resorted to using traditional medicine.
In resource-limited countries such as Malawi, the focus of
preventive MTCT has so far been on limiting the risk of
MTCT transmission around the time of delivery. However
there is a need to minimize the substantial HIV- transmission
that is still occurring through breast feeding. Cabergoline is
an acceptable, safe and effective drug that could be of signifi-
cant operational benefit in PMTCT programmes.
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SUMMARY Misconceptions about epilepsy may explain
the considerable stigmaaccompanying it.We aimed to
identify such fallacies through questionnaire-based inter-
views of 487 adult residents of a slum area in Karachi,
Pakistan. Of those interviewed, 25% believed that epilepsy
was caused byevil spirits, blackmagic and envy by others ^
thosewithout a school educationweremore likely to hold
these views (P , 0.05). Perceived complications
included impotence and cancer. Shoe-sniffing was
considered a treatment modality by 13%. It appears
that misconceptions abound regarding epilepsy’s
causes, complications and methods of treatment.
However, those who had received a school education
were less likely to link epilepsy with supernatural
phenomena.
Introduction
Epilepsy is one of the most common neurological illnesses.1
Epileptics comprise 1% of the Pakistani population and most
sufferers are under 19 years old.2
Negative attitudes toward epilepsy are prevalent across the
globe. Often the social stigma associated with epilepsy
becomes a greater handicap than the associated seizures or
the side-effects of medication.3,4
Negative attitudes arise from misconceptions and lack of
knowledge about the illness. A study by Qidwai et al.5
assessed the prevalence of myths and fallacies regarding
various health issues among patients visiting a family
medical centre in Pakistan. Only two questions were asked
about epilepsy: 13% believed that evil spirits could cause
epilepsy, while 73% thought that psychological stress could
do so. No other study assessing the misconceptions regarding
this illness in Pakistan has been published. Identification of
local misconceptions is important in order to increase aware-
ness and improve attitudes towards epilepsy. Our study exam-
ines the various myths and fallacies regarding epilepsy
among residents of a Karachi slum area.
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